MedTrace Logo

Dimenydrinate vs Ondansetron for PONV (DONV)

NCT05590936 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2022-12-08

No results posted yet for this study

Summary

This study will investigate the impact of dimenydrinate (H1-receptor antagonist) versus ondansetron (HT3-receptor antagonist) in postoperative nausea and vomiting, in surgery-related preoperative stress and in the incidence of postoperative complications that could lengthen the LOS in PACU and/or the overall LOS.

Conditions

  • PONV in Laparoscopic Cholocystectomies

Interventions

DRUG

Dimenhydrinate Tablets

2 hours preoperative per os administration of 50 mg dimenhydrinate

DRUG

Ondansetron iv

Intraoperative intravenous administration of 4 mg ondansetron

Sponsors & Collaborators

  • University of Thessaly

    lead OTHER

Principal Investigators

  • Elena Arnaoutoglou, MD, PhD · University of Thessaly

  • Konstantinos George Stamoulis, MD, PhD · University Hospital of Larissa

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2022-12-07
Completion
2022-12-07

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05590936 on ClinicalTrials.gov